Dev Prasad
Stock Analyst at Lucid Capital
(4.74)
# 659
Out of 4,988 analysts
20
Total ratings
76.5%
Success rate
81.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiated: Buy | $18 | $2.34 | +669.23% | 1 | Sep 17, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $59 | $34.24 | +72.31% | 1 | Sep 14, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $49 | $15.52 | +215.72% | 1 | Sep 8, 2026 | |
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $38 | $17.63 | +115.54% | 1 | Aug 20, 2026 | |
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $2.03 | +244.83% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $6.90 | +334.78% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.61 | +129.89% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $49 → $212 | $151.43 | +40.00% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Reiterated: Buy | $24 | $2.04 | +1,076.47% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $4.53 | +319.43% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4.00 | $0.40 | +900.00% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $1 | $0.3841 | n/a | 1 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $34.17 | n/a | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $5.41 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $3.87 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.05 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $16.58 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $1.98 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.18 | n/a | 1 | Dec 17, 2024 |
Genelux
Sep 17, 2026
Initiated: Buy
Price Target: $18
Current: $2.34
Upside: +669.23%
Faeth Therapeutics
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $59
Current: $34.24
Upside: +72.31%
Adlai Nortye Group
Sep 8, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $15.52
Upside: +215.72%
Eloxx Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $17.63
Upside: +115.54%
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.03
Upside: +244.83%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $6.90
Upside: +334.78%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.61
Upside: +129.89%
Palvella Therapeutics
Dec 15, 2025
Reiterated: Buy
Price Target: $49 → $212
Current: $151.43
Upside: +40.00%
InflaRx
Nov 10, 2025
Reiterated: Buy
Price Target: $24
Current: $2.04
Upside: +1,076.47%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $4.53
Upside: +319.43%
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.40
Upside: +900.00%
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.3841
Upside: n/a
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $34.17
Upside: n/a
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $5.41
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.87
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.05
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $16.58
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $1.98
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.18
Upside: n/a